Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18294304 | 0.86 | LRRK2 (0.34) | ELOVL1LMNAHCAR2HRH3 | |
| SCHEMBL12836062 | 0.81 | ELOVL1 (0.38) | ELOVL1HCAR2 | |
| SCHEMBL9963120 | 0.77 | LMNA (0.40) | ELOVL1LMNAHCAR2HRH3 | |
| SCHEMBL9963130 | 0.77 | HCAR2 (0.31) | HCAR2 | |
| SCHEMBL12534060 | 0.76 | ELOVL1 (0.42) | ELOVL1HCAR2 | |
| SCHEMBL23102137 | 0.76 | LMNA (0.42) | ELOVL1LMNAHCAR2HRH3 | |
| SCHEMBL9963128 | 0.75 | — | — | |
| SCHEMBL9963134 | 0.73 | ACHE (0.30) | — | |
| SCHEMBL24780626 | 0.72 | LMNA (0.33) | LMNAHRH3 | |
| SCHEMBL31318905 | 0.72 | ELOVL1 (0.39) | ELOVL1LMNAHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | ELOVL1 4025/4885LMNA 1824/4885HCAR2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.